KNTE News and Press, Kinnate Biopharma Inc. From 09/21/22

SAN FRANCISCO and SAN DIEGO, Sept. 21, 2022 (GLOBE NEWSWIRE) -- Kinnate Biopharma Inc . (Nasdaq: KNTE) (“Kinnate”), a clinical-stage precision oncology company, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for Kinnate&...

SAN FRANCISCO and SAN DIEGO, Sept. 15, 2022 (GLOBE NEWSWIRE) -- Kinnate Biopharma Inc . (Nasdaq: KNTE) (“Kinnate”), a clinical-stage precision oncology company, today announced that its chief executive officer, Nima Farzan , will participate in the Piper Sandler Heartl...

SAN FRANCISCO and SAN DIEGO, Aug. 30, 2022 (GLOBE NEWSWIRE) -- Kinnate Biopharma Inc . (Nasdaq: KNTE) (“Kinnate”), a clinical-stage precision oncology company, today announced that its chief executive officer, Nima Farzan , will participate in a fireside chat at the We...

Gainer: Kinnate Biopharma ( KNTE ) +5% . Kezar Life Sciences ( KZR ) +5% . BridgeBio Pharma ( BBIO ) +5% . Stronghold Digital Mining ( SDIG ) +3% . IDEAYA Biosciences ( IDYA ) +3% . Losers: Advanced Emissions Solutions ( ...

Kinnate Biopharma press release ( NASDAQ: KNTE ): Q2 GAAP EPS of -$0.62 beats by $0.03 . As of June 30, 2022, the total of cash and cash equivalents and investments was $279.6 million, exclusive of Kinnjiu’s cash. For further details see: Kinnate Bioph...

Phase 1 clinical trial for KIN-2787, the company’s investigational pan-RAF inhibitor, was initiated in Taiwan by Kinnjiu Biopharma Inc., Kinnate’s China joint venture U.S. Food and Drug Administration granted Orphan Drug Designation for KIN-2787 for the tre...

SAN FRANCISCO and SAN DIEGO, Aug. 02, 2022 (GLOBE NEWSWIRE) -- Kinnate Biopharma Inc . (Nasdaq: KNTE) (“Kinnate”), a clinical-stage precision oncology company, today announced that its chief executive officer, Nima Farzan , will participate in the “Bullseye - Ta...

SAN FRANCISCO and SAN DIEGO, May 26, 2022 (GLOBE NEWSWIRE) -- Kinnate Biopharma Inc . (Nasdaq: KNTE) (“Kinnate”), a biopharmaceutical company focused on the discovery and development of small molecule kinase inhibitors for difficult-to-treat, genomically defined cancers, t...

Kinnate Biopharma press release (NASDAQ:KNTE): Q1 GAAP EPS of -$0.61. As of March 31, 2022, the total of cash and cash equivalents and investments was $302.4 million, exclusive of Kinnjiu’s cash. Existing cash and cash equivalents and investments as of March 31, 2022 with budget reallo...

Initial monotherapy data from ongoing Phase 1 KN-8701 clinical trial expected in the fourth quarter of 2022 Announces initiation of the combination portion of Phase 1 KN-8701 clinical trial to evaluate its pan-RAF inhibitor, KIN-2787, with binimetinib in NRAS-mutant melanoma ...